UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

FORM 8-K

 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): May 23, 2012


 
HELIX BIOMEDIX, INC.
(Exact name of registrant as specified in its charter)
 

 
DELAWARE
033-20897-D
91-2099117
(State or other jurisdiction
of incorporation or organization)
(Commission
File Number)
(IRS Employer
Identification No.)
 
22118 20 th Avenue S.E., Suite 204
Bothell, Washington 98021
(425) 402-8400
 

(Address and telephone number of registrant’s principal executive offices)

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
 
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 

 
 
Item 5.07  Submission of Matters to a Vote of Security Holders.

The 2012 Annual Meeting of the Stockholders of Helix BioMedix, Inc. (the “Company”) was held on May 23, 2012, at which the following matters were approved as follows:

1.
 
The election of the following Class III directors to serve until the 2015 Annual Meeting of Stockholders or until each such director’s successor is elected and qualified:
 
Nominee
    For
     
Withheld  
Broker Non-Votes
 
R. Stephen Beatty
 
33,143,658
 
275,270
 
     6,996,500
 
John F. Clifford
 
33,208,734
 
210,194
 
     6,996,500
 
Lawrence Blake Jones
 
33,295,958
 
122,970
 
     6,996,500
 
 
2.
 
The ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2012:

For
 
    Against
 
   Abstain
 
Broker Non-Votes
 
        40,054,127
 
  348,039
 
  13,262
    0
 

  These are the final voting results.
 
 
2

 
 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
         
     
HELIX BIOMEDIX, INC.
       
Dated: May 24, 2012
 
By:
 /s/ R. Stephen Beatty
       
R. Stephen Beatty
       
President and Chief Executive Officer


Helix Biomedix (PK) (USOTC:HXBM)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024 Plus de graphiques de la Bourse Helix Biomedix (PK)
Helix Biomedix (PK) (USOTC:HXBM)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024 Plus de graphiques de la Bourse Helix Biomedix (PK)